Septerna (SEPN) COO Elizabeth Bhatt Sells $150K of Stock

By TradeTexts Research Desk Oct 19, 2026, 7:02 PM EDT

Key Points

Elizabeth Bhatt, President and COO of Septerna, Inc., sold 4,000 shares on October 15, 2026, at an average price of $37.41.
After the trade, Elizabeth Bhatt holds 174,209 $SEPN shares, down 2.24% from before the trade.
The biotechnology company reported $98.88 million in trailing twelve-month revenue ahead of its November 9, 2026 earnings report.
Wall Street analysts maintain a consensus buy rating on Septerna with an average price target of $54.22.

Since the trade, $SEPN is down 2.9% to date (from the $37.45 close on Oct 15, 2026).

Get Septerna text alerts

We text you when insiders, Congress, analysts or big funds move on $SEPN.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Septerna, Inc. alert may contain errors. Disclosures

Elizabeth Bhatt, President and COO of Septerna, Inc., sold 4,000 shares of the biotechnology company on October 15, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the transaction was executed at an average price of $37.41 for a total value of $149,644.40. The stock closed at $37.45 on the day of the trade.

SEPN Septerna, Inc.

$36.38 +30.02% year to date

Daily close · Oct 19, 2026

Inside Elizabeth Bhatt's Septerna Trade

The sale was completed under a pre-arranged Rule 10b5-1 trading plan. Following the trade, Bhatt directly holds 174,209 shares of the company, which represents a 2.24% decrease in her personal holdings.

Other Institutional Activity in Septerna, Inc.

Institutional investors have been adjusting their positions in the biotech firm over recent quarters. RA Capital Management, L.P. held 6,995,858 shares valued at $254,509,321. Trv Gp V, LLC maintained a stake of 6,215,591 shares worth about $226,123,207. Driehaus Capital Management, LLC grew its holdings by 37,363 shares, ending the period with 4,433,058 shares valued at about $161,274,654.

Septerna, Inc. Stock Up 0.1%

Shares recently traded around $36.38 as of October 19, 2026, down about 2.9% since the transaction date. The stock sits below its 50-day moving average of $39.38 but remains above its 200-day moving average of $31.31.

Recent Earnings

Septerna reported trailing twelve-month revenue of $98,882,000 alongside a negative basic earnings per share of $0.54. The clinical-stage firm posted a net margin of -24.5% and a return on equity of -6.3%. Its current ratio stands at 4.995, with a quick ratio of 4.895 and a debt-to-equity ratio of 5.83. The company is scheduled to release its next financial results on November 9, 2026.

Insider Buying and Selling at Septerna, Inc.

Earlier in the year, several individuals associated with the company engaged in transactions. On June 26, 2026, Shalani Sharp, L.P. Ra Capital Management, Alan Ezekowitz, and Bernard Coulie each acquired 15,000 shares.

Analysts Set New Price Targets

Wall Street firms continue to cover the stock with favorable ratings. On August 11, 2026, Guggenheim maintained its Buy rating with a target of $51.00. Wells Fargo kept an Overweight rating and raised its target to $50.00 on August 12, 2026. On the same day, HC Wainwright & Co. maintained a Buy rating and increased its target to $60.00. Jones Trading maintained a Buy rating with a $62.00 target on August 13, 2026, while JP Morgan maintained an Overweight rating and raised its target to $48.00 on August 19, 2026. Overall, nine analysts carry a consensus buy recommendation on the stock with a mean price target of $54.22.

About Septerna, Inc.

Septerna, Inc. is a clinical-stage biotechnology company based in South San Francisco, California. The firm focuses on discovering and developing G protein-coupled receptor oral small molecule products to treat endocrinology, immunology, inflammation, and metabolic diseases.

Bottom Line

Investors will look toward Septerna's upcoming earnings report on November 9, 2026, for updates on its clinical pipeline and financial trajectory. Insider transactions and institutional filing shifts will continue to provide signals on how major stakeholders view the company's progress.